These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 1363474)

  • 1. Activation of CD4+ and CD8+ lymphocyte subsets by streptozotocin in the popliteal lymph node assay. II. Comparison with acute graft-vs-host reaction in H-2 incompatible F1 mouse hybrids.
    Krzystyniak K; Panaye G; Descotes J; Revillard JP
    Immunopharmacol Immunotoxicol; 1992; 14(4):865-82. PubMed ID: 1363474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of CD4+ and CD8+ lymphocyte subsets by streptozotocin in murine popliteal lymph node (PLN) test.
    Krzystyniak K; Brouland JP; Panaye G; Patriarca C; Verdier F; Descotes J; Revillard JP
    J Autoimmun; 1992 Apr; 5(2):183-97. PubMed ID: 1352686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of L3T4+ and Lyt-2+ donor cells in graft-versus-host immune deficiency induced across a class I, class II, or whole H-2 difference.
    Moser M; Sharrow SO; Shearer GM
    J Immunol; 1988 Apr; 140(8):2600-8. PubMed ID: 3258615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-receptor anti-MHC cytotoxic T lymphocytes: their role in the resistance to graft vs host reaction.
    Kosmatopoulos K; Algara DS; Orbach-Arbouys S
    J Immunol; 1987 Feb; 138(4):1038-41. PubMed ID: 3492538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of polyinosinic:polycytidylic acid (pI:C) on the graft-vs-host (GVH) reaction. II. Increased NK-mediated rejection on C57BL/6 lymphocytes by (C57BL/6 X A)F1 mice.
    Peres A; Nestel FP; Seemayer TA; Lapp WS
    J Immunol; 1986 Dec; 137(11):3420-7. PubMed ID: 3537120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attempts at standardization of lupus-like graft-vs-host disease: inadvertent repopulation by DBA/2 spleen cells of H-2-different nonirradiated F1 mice.
    Van Rappard-Van Der Veen FM; Radaszkiewicz T; Terraneo L; Gleichmann E
    J Immunol; 1983 Jun; 130(6):2693-701. PubMed ID: 6602176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A.
    Rolink AG; Pals ST; Gleichmann E
    J Exp Med; 1983 Feb; 157(2):755-71. PubMed ID: 6218218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of CD8+ cells exacerbates organ-specific autoimmune diseases induced by CD4+ T cells in semiallogeneic hosts with MHC class II disparity.
    Saitoh T; Ikarashi Y; Ito S; Watanabe H; Fujiwara M; Asakura H
    J Immunol; 1990 Nov; 145(10):3268-75. PubMed ID: 2121823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
    Via CS; Sharrow SO; Shearer GM
    J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GVHR elicited by products of class I or class II loci of the MHC: analysis of the response of mouse T lymphocytes to products of class I and class II loci of the MHC in correlation with GVHR-induced mortality, medullary aplasia, and enteropathy.
    Piguet PF
    J Immunol; 1985 Sep; 135(3):1637-43. PubMed ID: 2410497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-vs-host reactions (GVHR) across minor murine histocompatibility barriers. II. Development of natural suppressor cell activity.
    Maier T; Holda JH; Claman HN
    J Immunol; 1985 Sep; 135(3):1644-51. PubMed ID: 3160774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated peripheral T cells from GvHR recipients exhibit defective IL-2R expression, IL-2 production, and proliferation in response to activation stimuli.
    Levy RB; Jones M; Cray C
    J Immunol; 1990 Dec; 145(12):3998-4005. PubMed ID: 1979582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of proliferative capacity and T cell immune development potential by bone marrow from mice undergoing a graft-vs-host reaction.
    Iwasaki T; Fujiwara H; Iwasaki T; Shearer GM
    J Immunol; 1986 Nov; 137(10):3100-8. PubMed ID: 2945856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition and response to alloantigens in vivo. I. Negative and positive selection of MLR reactivity in murine peripheral blood lymphocytes to major histocompatibility complex and Mls antigens.
    Ryan JJ; Ahmed A; Kind PD; Thompson CB; Berning AK; Sell KW
    J Immunol; 1984 Aug; 133(2):606-15. PubMed ID: 6234352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of T cell populations after acute graft-vs-host reaction.
    Hakim FT; Payne S; Shearer GM
    J Immunol; 1994 Jan; 152(1):58-64. PubMed ID: 8254206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosuppressor- and allohelper-T cells in acute and chronic graft-vs-host disease. IV. Activation of donor allosuppressor cells is confined to acute GVHD.
    Pals ST; Radaszkiewicz T; Gleichmann E
    J Immunol; 1984 Apr; 132(4):1669-78. PubMed ID: 6230390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-vs-host reactions (GVHR) across minor murine histocompatibility barriers. I. Impairment of mitogen responses and suppressor phenomena.
    Holda JH; Maier T; Claman HN
    J Immunol; 1985 Mar; 134(3):1397-402. PubMed ID: 3155767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of the induction of autoimmune disease by graft-versus-host reaction. Role of CD8+ cells in the development of hepatic and ductal lesions induced by CD4+ cells in MHC class I plus II-different host.
    Suzuki K; Narita T; Yui R; Asakura H; Fujiwara M
    Lab Invest; 1994 May; 70(5):609-19. PubMed ID: 8196358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection from lethal graft-vs.-host disease by donor stem cell repopulation.
    Rozendaal L; Pals ST; Melief CJ; Gleichmann E
    Eur J Immunol; 1992 Feb; 22(2):575-9. PubMed ID: 1347016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.